Neutrophil A(2A) adenosine receptor inhibits inflammation in a rat model of meningitis: Synergy with the type IV phosphodiesterase inhibitor, rolipram

Journal of Infectious Diseases

Volumn 180, Issue 5, 1999, Pages 1550-1560

  Sullivan, Gail W ^a,c   Linden, Joel ^a   Buster, Bradley L ^a,b   Scheld, W Michael ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b Univ of Virginia Hlth Sci Center ^*  (United States)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; ADENOSINE A2A RECEPTOR; ADENOSINE RECEPTOR STIMULATING AGENT; BINODENOSON; PHOSPHODIESTERASE INHIBITOR; ROLIPRAM; UNCLASSIFIED DRUG; 2 (CYCLOHEXYLMETHYLIDENEHYDRAZINO)ADENOSINE; 2-(CYCLOHEXYLMETHYLIDENEHYDRAZINO)ADENOSINE; ADENOSINE; ADENOSINE RECEPTOR; CYCLIC AMP; DRUG DERIVATIVE; SUPEROXIDE; TRIAZINE DERIVATIVE; TRIAZOLE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL MENINGITIS; BINDING AFFINITY; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DEGRANULATION; DOSE RESPONSE; HUMAN; HUMAN CELL; LEUKOCYTE MIGRATION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PLEOCYTOSIS; PRIORITY JOURNAL; RAT; SUBARACHNOID SPACE; ANIMAL; CELL ADHESION; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; IMMUNOLOGY; LEUKOCYTE ACTIVATION; LEUKOCYTOSIS; METABOLISM; NEUTROPHIL; PHYSIOLOGY; RESPIRATORY BURST; WISTAR RAT;

ADENOSINE; ANIMALS; BLOOD-BRAIN BARRIER; CELL ADHESION; CYCLIC AMP; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; HUMANS; LEUKOCYTOSIS; MENINGITIS, BACTERIAL; NEUTROPHIL ACTIVATION; NEUTROPHILS; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, WISTAR; RECEPTOR, ADENOSINE A2A; RECEPTORS, PURINERGIC P1; RESPIRATORY BURST; ROLIPRAM; SUPEROXIDES; TRIAZINES; TRIAZOLES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032589411     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315084     Document Type: Article

References (64)

1. 1. Tucker AL, Linden J. Cloned receptors and cardiovascular responses to adenosine. Cardiovasc Res 1993;27:62-7.
2. 2A adenosine receptors in inflammation. Drug Dev Res 1998;45:103-12.
3. 2 receptor on human neutrophils. J Immunol 1985;135:1366-71.
4. 4. Schrier DJ, Imre KM. The effects of adenosine agonists on human neutrophil function. J Immunol 1986;137:3284-9.
5. 5. Martini C, Di Saeco S, Tacchi P, et al. A. adenosine receptors in neutrophils from healthy volunteers and patients with rheumatic disease. In: Harkness RA, Elion GB, Zöllner N, eds. Purine and pyrimidine metabolism in man. New York: Plenum Press, 1991:459-62.
6. 2 receptors. J Immunol 1992;148: 2201-6.
7. 7. Rose FR, Hirshhorn R, Weissmann G, Cronstein BN. Adenosine promotes neutrophil chemotaxis. J Exp Med 1988;167:1186-94.
8. 2 receptors are inhibitory. J Immunol 1990;145:2235-40.
9. 9. Cronstein BN, Kramer SB, Weissmann G, Hirschhorn R. Adenosine: a physiological modulator of superoxide anion generation by human neutrophils. J Exp Med 1983;158:1160-77.
10. 2) release by activated human neutrophils. Clin Immunol Immunopathol 1987;42:76-85.
11. 11. De La Harpe J, Nathan CF. Adenosine regulates the respiratory burst of cytokine-triggered human neutrophils adherent to biological surfaces. J Immunol 1989;143:596-602.
12. 12. Nielson CP, Vestal RE. Effects of adenosine on polymorphonuclear leucocyte function, cyclic 3′:5′-adenosine monophosphate and intracellular calcium. Br J Pharmacol 1989;97:882-8.
13. 13. Sacks T, Moldow CF, Craddock PR, Bowers TK. Oxygen radicals mediate endothelial cell damage by complement-stimulated granulocytes; an in vitro model of immune vascular damage. J Clin Invest 1978;61:1161-7.
14. 14. Sullivan GW, Carper HT, Manuell GL. The specific type IV phosphodiesterase inhibitor rolipram combined with adenosine reduces tumor necrosis factor-α primed neutrophil osidative activity. Int J Immunopharmacol 1995;17:793-803.
15. 15. Sullivan GW, Luong LS, Carper HT, Barnes CR, Mandell GL. Methylxanthines with adenosine alter TNF-α-primed PMNL activation. Immunopharmacology 1995;31:19-29.
16. 16. Barnes CR, Mandell GL, Carper HT, Luong S, Sullivan GW. Adenosine modulation of tumor necrosis factor-α induced neutrophil activation. Biochem Pharmacol 1995;50:1851-7.
17. 17. Sullivan GW, Linden J, Hewlett EL, Carper HT, Hylton JB, Mandell GL. Adenosine and related compounds counteract tumor necrosis factor-α inhibition of neutrophil migration: implication of a novel cyclic AMP-independent action on the cell surface. J Immunol 1990;145:1537-44.
18. 18. Zhang Y, Fredholm BB. Propentoxifylline enhancement of the actions of adenosine on neutrophil leukocytes. Biochem Pharmacol 1994;48: 2025-32.
19. 19. Iannone MA, Zimmerman TP, Reynolds-Vaughn R, Wolberg G. Effects of adenosine on human neutrophil function and cyclic AMP content. In: Gerlach E, Becker BF, eds. Topics and perspectives in adenosine research. Berlin: Springer-Verlag, 1987:286-98.
20. 3 receptors. J Immunol 1997;158: 5400-8.
21. 21. Richter J. Effect of adenosine analogues and cAMP-ruising agents on TNF-α GM-CSF, and chemotactic peptide-induced degranulation in single adherent neutrophils. J Leukoc Biol 1992;51:270-5.
22. 22. Semmler J, Wachtel H, Endres S. The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cells. Int J Immunopharmacol 1993;15:409-13.
23. 23. Eigler A, Greten TF, Sinha B, Haslberger C, Sullivan GW, Endres S. Endogenous adenosine curtails lipopolysaccharide-stimulated tumour necrosis factor synthesis. Scand J Immunol 1997;45:132-9.
24. 24. Wright CD, Kuipers PJ, Kobylarz-Singer D, Devall LJ, Klinkefus BA, Weishaar RE. Differential inhibition of human neutrophil functions. Biochem Pharmacol 1990;40:699-707.
25. 25. Cronstein BN, Kramer SB, Rosenstein ED, Korchak HM, Weissmann G, Hirshhorn R. Occupancy of adenosine receptors raises cyclic AMP alone and in synergy with occupancy of chemoattractant receptors and inhibits membrane depolarization. Biochem J 1988;252:709-15.
26. 2A adenosine receptor agonist 2-hexynyl-5'-N-ethylcarbozamidoadenosine. Arzneimittelforschung 1996;44:1296-304.
27. 27. Heaslip RJ, Evans DY. Emetic, central nervous system and pulmonary activities of rolipram in the dog. Eur J Pharmacol 1995;286:281-90.
28. 28. Quagliarello VJ, Scheld WM. Treatment of bacterial meningitis. N Engl J Med 1997;336:708-16.
29. 29. Quagliarello V, Scheld WM. Bacterial meningitis: pathogenesis, pathophysiology and progress, N Engl J Med 1992;327:864-72.
30. 30. Lesse AJ, Moxon ER, Zwahlen A, Scheld WM. Role of cerebrospinal fluid pleocytosis and Haemophilus influenzae type b capsule on blood-brain barrier permeability during experimental meningitis in the rat. J Clin Invest 1988;82:102-9.
31. 31. Qualiarello V, Wispelwey B, Long WJ, Scheld WM. Recombinant human interleukin-1 induces meningitis and blood-brain burrier injury in the rat: characterizalion and comparison with tumor necrosis factor. J Clin Invest 1991;87:1360-6.
32. 2 adenosine receptor. Mol Pharmacol 1995;48:970-1.
33. 33. Niiya K, Thompson RD, Silvia SK, Olsson RA. 2-(n'-araldylideneliydrazino) adenosines: potent and selective coronary vasodilators. J Med Chem 1992;35:4562-6.
34. 2A) receptor agonist that produces selective coronary vasodilation. Drug Dev Res 1997;40:313-24.
35. 35. Ferrante A, Thong YH. Optimal conditions for simultaneous purification of mononuclear and polymorphonuclear leukocytes from human blood by the hypaque-ficoll method. J Immunol Methods 1980;36:109-17.
36. 2A selective adenosine receptor antagonist. Br J Pharmacol 1995;115:1096-102.
37. 2A receptor antagonist. Eur J Pharmacol 1996;301:107-13.
38. 2A-adenosine receptors with hexahistidine and the FLAG epitope development of an efficient generic protein purification procedure. Biochem Pharmacol 1996;51:545-55.
39. 39. Brooker B, Terasaki WL, Price MB. Gummaflow: a completely automated radioimmunoassay system. Science 1976;194:270-6.
40. 40. Stowell CP, Kuhlenschmidt TG, Hoppe CA. A fluorescamine assay for submicrogram quantities of proiein in the presence of Triton-X 100. Anal Biochem 1978;85:572-80.
41. 41. Van Gelder BF, Slate EC. The extinction coefficient cytochromec. Biochim Biophys Acta 1962;58:593-6.
42. 42. Rothe G, Emmendorffer A, Oser A, Rooster J, Valet G. Flow cytometric measurement of the respiratory burst activity of phagocytes using dihydrorhodamine 123. J Immunol Methods 1991;138:133-5.
43. 43. Sullivan GW, Mandell GL. Interactions of human neutrophils with leukotoxic streptococci. Infect Immun 1980;30:272-80.
44. 44. Smolelis AN, Hartsell SE. The determination of lysozyme. J Bacteriol 1949;58:731-6.
45. 2A rctcptors mediate the inhibitory effect of adenosine on formyl-met-leu-phe-stimulated respiratory burst in neutrophil leukocytes. Naunyn Schmiedebergs Arch Pharmacol 1996;354:262-7.
46. 46. Shalaby MR, Palladino MA Jr, Hirabayashi SE, et al. Receptor binding and activation of polymorphonuclear neutrophils by tumor necrosis factor-alpha. J Leukoc Biol 1987;41:196-204.
47. 47. Stewart AG, Harris T. Adenosine inhibits platelet-activating factor, but not tumour necrosis factor-α induced priming of human neutrophils. Immunology 1993;78:152-8.
48. 48. Nathan CF. Neutrophil activation on biological surfaces. Massive secretion of hydrogen peroxide in response to products of macrophages and lymphocytes. J Clin Invest 1987;80:1550-60.
49. 49. Nathan CF, Sanchez E. Tumor necrosis factor and CD11/CD18 (β2) integrins act synergistically to lower cAMP in human neutrophils. J Cell Biol 1990;111:2171-81.
50. 50. Marone G, Lichtenstein TL. The role of agonists that activate adenylate cyclasse in the control of cAMP metabolism and enzyme release by human polymorphonuclear leukocytes. J Immunol 1980;125:2277-83.
51. 51. Platzer C, Meisel C, Vogt K, Platzer M, Volk HD. Up-regulation of monocytic IL-10 by tumor necrosis factor-α and cAMP elevating druga. Int Immunol 1995;7:517-23.
52. 52. Fuortes M, Nathan C. Role of CD11/CD18 integrins and cAMP in TNF-induced respiritory burst of human neutrophils. In: Jesailis AJ, Dratz EA, eds. The molecular basis of oxidative damage by leukocytes. Boca Raton, FL: CRC Press, 1992:81-90.
53. 558 of NADPH oxidase by phosphorylation of Rap1A. Sciene 1991;254:1794-6.
54. 54. Lang P, Gesbert F, Delespine-Carmagnat M, Stancou R, Pouchelet M, Bertoglio J. Protein kinase A phosphorylation of RhoA mediates the morphological and functional effects of cyclic AMP in cytotoxic lymphocytes. EMBO J 1996;15:510-9.
55. 55. Laudanna C, Campbell JJ, Butcher C. Role of Rho in chemoattractant-activated leukocyte adhesion through integrins. Science 1996;271:981-3.
56. 56. Laudanna C, Campbell JJ, Butcher EC. Elevation of intracellular cAMP inhibits RhoA activation and integrin-dependent leukocyte adhesion induced by chemoattractants. J Biol Chem 1997;272:24141-4.
57. 57. Bowman EP, Uhlinger DJ, Lambeth JD. Neutrophil phospholipase D is activated by a membrane-associated Rho family small molecular weight GTP-binding protein. J Biol Chem 1993;268:21509-12.
58. 58. Frank MO, Sullivan GW, Carper HT, Mandell GL. Inhibition of phospholipase D blocks activation of fibrinogen-adherent neutrophils by tumor necrosis factor. Infect Immun 1994;62:2622-4.
59. 59. Bouma MG, Stad RK, Van den Wildenberg FAJM, Buurmun WA. Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J Immunol 1994;153:4159-68.
60. 2 receptors on rat kupffer cells. He-patology 1994;19:1445-52.
61. 61. Hasko G. Szabo C, Nemeth Z, Kvetan V, Pastores SM, Vizi ES. Adenosine receptor agonists differentially regulate IL-10, TNK-α, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J Immunol 1996;157:4634-40.
62. 62. Prabhakar U, Lipshultz D, Bartus JO, et al. Characterization of cAMP-dependent inhibition of LPS-induced TNFα production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. Int J Immunopharmacol 1994;16:805-16.
63. 63. Bouma MG, Vandenwildenberg FAJM, Buurman WA. Adenosine inhibits cytokine release and expression of adhesion molecules by activated human endothelial cell. Am J Physiol 1996;39:C522-9.
64. 64. Lundblad R, Ekstrom P, Giercksky KE. Pentoxifylline improves survival and reduces tumor necrosis factor, interleukin-6, and endothelin-1 in fulminant intra-abdominal sepsis in rats. Shock 1995;3:210-5.